返回
F
Fundació Puigvert
学者数161
论文数44
被引数0
关联论文 (44)
发表时间
Reply to Paolo Zaurito, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Daria Chernysheva, Francesco Di Bello, Giulio Avesani et al. ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.06.012回复Paolo Zaurito、Giorgio Gandaglia和Francesco Montorsi致编辑的信:关于Daria Chernysheva、Francesco Di Bello、Giulio Avesani等人。ProBIOPSY:关于前列腺活检标准的国际多学科共识。Eur Urol。待发表。https://doi.org/10.1016/j.eururo.2026.06.012
European Urology
IF25.2
Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404–12回复:罗伯托·孔特里尔、马可·帕奇奥蒂、亚历山德罗·乌莱里等人。对于T1非肌层浸润性膀胱癌的特定患者,第二次经尿道膀胱肿瘤切除术可安全省略:来自前瞻性HuNIRe试验的结果。欧洲泌尿肿瘤学2026;9:404–12
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol 2026;89:437–45关于:北村浩一、塚本彻、笔井义明等。对于二次经尿道切除术阴性的高危T1膀胱癌,主动监测与膀胱内卡介苗治疗的比较:随机非劣效性III期JCOG1019试验。欧洲泌尿学杂志2026;89:437–45。
European Urology
IF25.2
Re: Gallagher et al. RESECT, A Randomised Controlled Trial of Audit and Feedback in Non–muscle-invasive Bladder Cancer Surgery. Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2025.09.4174致Gallagher等人:RESECT,一项关于非肌层浸润性膀胱癌手术中审计与反馈的随机对照试验。欧洲泌尿学杂志,2026年。待发表。http://dx.doi.org/10.1016/j.eururo.2025.09.4174
European Urology
IF25.2

